Compared with the CHRM2 low expression group, the CHRM2 highly-expressed group contained upregulation of tumor-promoting pathways including endometrial cancer, Wnt signaling pathway, and estrogen signaling pathway. Here, CHRM2 is linked to endometrial cancer.